September 19, 2011

U.S. District Court Rules in Favor of Sanofi U.S. in Eloxatin® Patent Litigation

- Eloxatin®’s US market exclusivity maintained through August 2012 -

 

U.S. District Court Rules in Favor of Sanofi U.S. in Eloxatin® Patent Litigation
- Eloxatin®’s US market exclusivity maintained through August 2012 -

Paris, France – September 19, 2011 – Sanofi (EURONEXT:SAN and NYSE: SNY) announced today that the U.S. District Court for the District of New Jersey has ruled against Sun Pharmaceuticals LTD. (Sun) in favor of Sanofi U.S. with respect to a contractual dispute arising from the resolution of the Eloxatin® (oxaliplatin) patent litigation.